{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:25:52Z","timestamp":1792794352554,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse-S\u00f8r \u00d8st","doi-asserted-by":"crossref","award":["2019088"],"award-info":[{"award-number":["2019088"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006095","name":"Helse-S\u00f8r \u00d8st","doi-asserted-by":"crossref","award":["2021042"],"award-info":[{"award-number":["2021042"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006095","name":"Helse-S\u00f8r \u00d8st","doi-asserted-by":"crossref","award":["2022058"],"award-info":[{"award-number":["2022058"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["223187"],"award-info":[{"award-number":["223187"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2020851"],"award-info":[{"award-number":["2020851"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2038108"],"award-info":[{"award-number":["2038108"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Council Victoria Grants-In-Aid","id":[{"id":"https:\/\/ror.org\/023m51b03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression. Here, we evaluated the association between aprepitant and survival in a large cohort of women with early breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using linked nationwide registry data, we identified 13\u00a0811 women diagnosed with early breast cancer between 2008 and 2020 in Norway, who received chemotherapy and antiemetics. Women were followed for metastasis and death from 1 year after diagnosis until the end of 2021. To evaluate the association between aprepitant use and distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS), we used Cox regression models, controlling for tumor and patient characteristics, chemotherapy regimens, and use of other antiemetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During chemotherapy, 7047 (51%) women were supplied with aprepitant. Overall, aprepitant use was associated with better DDFS (HRDDFS = 0.89; 95% CI = 0.79 to 1.00) and BCSS (HRBCSS = 0.83; 95% CI = 0.71 to 0.97). The survival advantage was specific to women with non-luminal breast cancer (HRDDFS = 0.69; 95% CI = 0.56 to 0.83; HRBCSS = 0.64; 95% CI = 0.51 to 0.81) and was strongest in women with triple negative breast cancer (TNBC) (HRDDFS = 0.66; 95% CI = 0.53 to 0.83; HRBCSS = 0.61; 95% CI = 0.47 to 0.80). In women with non-luminal breast cancer, longer durations of aprepitant use were associated with increasingly favorable survival outcomes (DDFS: Ptrend = .002; BCSS: Ptrend = .016). Supply of other antiemetics of different drug classes was not associated with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf178","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:23:25Z","timestamp":1751873005000},"page":"2249-2258","source":"Crossref","is-referenced-by-count":16,"title":["Aprepitant use during chemotherapy and association with survival in women with early breast cancer"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-8068","authenticated-orcid":false,"given":"Edoardo","family":"Botteri","sequence":"first","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]},{"name":"Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-5868","authenticated-orcid":false,"given":"Sarah","family":"Hjorth","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-0502","authenticated-orcid":false,"given":"Fabio","family":"Conforti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Humanitas Gavazzeni , Bergamo,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[{"name":"Department of Statistics and Quantitative Methods, University of Milan-Bicocca , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5087-2913","authenticated-orcid":false,"given":"Bettina K","family":"Andreassen","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8994-9332","authenticated-orcid":false,"given":"Nathalie C","family":"St\u00f8er","sequence":"additional","affiliation":[{"name":"Department of Research, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2770-584X","authenticated-orcid":false,"given":"Sameer","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]},{"name":"Department of Oncology, Akershus University Hospital , L\u00f8renskog,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-9507","authenticated-orcid":false,"given":"Giske","family":"Ursin","sequence":"additional","affiliation":[{"name":"Cancer Registry of Norway, Norwegian Institute of Public Health , Oslo,","place":["Norway"]},{"name":"Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo ,","place":["Norway"]},{"name":"Department of Preventive Medicine, University of Southern California , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4548","authenticated-orcid":false,"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, European Institute of Oncology IRCCS , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-1433","authenticated-orcid":false,"given":"Erica K","family":"Sloan","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University , Parkville, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-516X","authenticated-orcid":false,"given":"Aeson","family":"Chang","sequence":"additional","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences, Monash University , Parkville, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025110923124231200_djaf178-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025110923124231200_djaf178-B2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med"},{"key":"2025110923124231200_djaf178-B3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025110923124231200_djaf178-B4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"2025110923124231200_djaf178-B5","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/1078-0432.Ccr-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER Database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025110923124231200_djaf178-B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician\u2019s choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025110923124231200_djaf178-B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","article-title":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference","volume":"17","author":"Roila","year":"2006","journal-title":"Ann Oncol"},{"key":"2025110923124231200_djaf178-B8","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025110923124231200_djaf178-B9","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/cancers12092682","article-title":"The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?","volume":"12","author":"Mu\u00f1oz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025110923124231200_djaf178-B10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-013-2599-6","article-title":"Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer","volume":"140","author":"Zhou","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2025110923124231200_djaf178-B11","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","article-title":"The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer","volume":"45","author":"Mu\u00f1oz","year":"2014","journal-title":"Int J Oncol"},{"key":"2025110923124231200_djaf178-B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41586-024-07767-5","article-title":"Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis","volume":"633","author":"Padmanaban","year":"2024","journal-title":"Nature"},{"key":"2025110923124231200_djaf178-B13","doi-asserted-by":"publisher","first-page":"e12527","DOI":"10.1111\/cpr.12527","article-title":"MiR-34b\/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis","volume":"52","author":"Zhang","year":"2019","journal-title":"Cell Prolif"},{"key":"2025110923124231200_djaf178-B14","author":"Cancer Registry of Norway"},{"key":"2025110923124231200_djaf178-B15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1403494819859737","article-title":"The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: research potential of two nationwide health-care registries","volume":"48","author":"Bakken","year":"2020","journal-title":"Scand J Public Health"},{"key":"2025110923124231200_djaf178-B16","author":"Norwegian Prescription Database (NorPD)"},{"key":"2025110923124231200_djaf178-B17","author":"Statistics Norway (SSB)"},{"key":"2025110923124231200_djaf178-B18","author":"Cause of Death Registry"},{"key":"2025110923124231200_djaf178-B19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijmedinf.2019.03.004","article-title":"Using clinical cancer registry data for estimation of quality indicators: results from the Norwegian breast cancer registry","volume":"125","author":"Hartmann-Johnsen","year":"2019","journal-title":"Int J Med Inform"},{"key":"2025110923124231200_djaf178-B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5324\/nje.v29i1-2.4043","article-title":"INSPIRE: a new opportunity for cancer pharmacoepidemiology research","volume":"29","author":"Enerly","year":"2021","journal-title":"Norsk Epidemiologi"},{"key":"2025110923124231200_djaf178-B21","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"2025110923124231200_djaf178-B22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/14034948231214580","article-title":"National health registries\u2014a 'goldmine\u2019 for studying non-communicable disease occurrence in Norway\u2014the NCDNOR project","volume":"52","author":"Nystad","year":"2023","journal-title":"Scand J Public Health"},{"key":"2025110923124231200_djaf178-B23","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2025110923124231200_djaf178-B24","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"2025110923124231200_djaf178-B25","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/annonc\/mdv478","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"key":"2025110923124231200_djaf178-B26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2025110923124231200_djaf178-B27","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"2025110923124231200_djaf178-B28","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025110923124231200_djaf178-B29","first-page":"44","article-title":"Akynzeo (netupitant and palonosetron), a dual-acting oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"2025110923124231200_djaf178-B30","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek","year":"2021","journal-title":"The Oncologist (Dayton, Ohio)"},{"key":"2025110923124231200_djaf178-B31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41523-022-00485-z","article-title":"Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3","volume":"8","author":"Le","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2025110923124231200_djaf178-B32","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025110923124231200_djaf178-B33","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.23937\/2378-3419\/3\/6\/1071","article-title":"Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels","volume":"3","author":"Lee","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"2025110923124231200_djaf178-B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/mco.2019.1857","article-title":"Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: a case report","volume":"11","author":"Mu\u00f1oz","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2025110923124231200_djaf178-B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0197-4580(85)90056-9","article-title":"Effect of age on substance P levels in the rat mesenteric artery and vein","volume":"6","author":"Duckles","year":"1985","journal-title":"Neurobiol Aging"},{"key":"2025110923124231200_djaf178-B36","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jpain.2017.04.006","article-title":"Age differences in the time course and magnitude of changes in circulating neuropeptides after pain evocation in humans","volume":"18","author":"Riley","year":"2017","journal-title":"J Pain"},{"key":"2025110923124231200_djaf178-B37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12032-024-02312-w","article-title":"The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: in vitro and in vivo study","volume":"41","author":"Alalikhan","year":"2024","journal-title":"Med Oncol"},{"key":"2025110923124231200_djaf178-B38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jhep.2013.12.024","article-title":"Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo","volume":"60","author":"Berger","year":"2014","journal-title":"J Hepatol"},{"key":"2025110923124231200_djaf178-B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13153871","article-title":"Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis","volume":"13","author":"Rodriguez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025110923124231200_djaf178-B40","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1007\/s00520-018-4259-1","article-title":"Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study","volume":"26","author":"De Laurentiis","year":"2018","journal-title":"Support Care Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf178\/63727523\/djaf178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2249\/63727523\/djaf178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/11\/2249\/63727523\/djaf178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T04:12:47Z","timestamp":1762747967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/11\/2249\/8196554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,14]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf178","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,14]]}}}